The cancer screening market is witnessing a rapid upsurge due to a rapid rise in the number of cancer cases. There lies an immediate need to seek early diagnosis and precautionary measures. The growth of the market lies in the adoption of innovative screening technologies to cater to the cause. High-scale investments are being adopted by entities on diagnostic instruments along with collaboration with the government to ensure instrument accessibility. The global cancer screening market is expected to grow at a compound annual growth rate (CAGR) of 11% during the forecast period. The market is expected to return a revenue of USD 152.10 Bn by 2023.

The cancer screening market is segmented based on the type of end users (hospitals, laboratory, independent physicians and clinics), screening type (laboratory, genetic, imaging, biopsy, and endoscopy) and application type (lung, breast, melanoma, kidney and colorectal). North America and Europe will be the leading regions for the market. Asia-Pacific is the fastest growing region for the cancer screening market while Latin America needs to work on its economic scenario to fulfil the region’s growing need for cancer diagnosis.

Key growth factors

The rise in the number of cancer cases and growing awareness among people to seek preventive measures along with government-centered initiatives towards cancer prevention is driving the cancer screening market. Prevention calls for innovative methodologies and technologies to be accessible for early diagnosis.

Threats and key players

There lies an underlying threat to provide affordable and accessible treatment to all. Along with this providing transparency and safety of medical procedures will be a key challenge for the cancer screening market.
The key players operating in this market are GE healthcare (Illinois), Siemens Healthineers (Germany), Abbott Diagnostics (U.S.), F.Hoffmann-La Roche (Switzerland), Thermo Fisher Scientific (U.S.), Hologic Inc. (U.S.), Becton Dickinson and Company (New Jersey), Qiagen (Germany), Philips (Netherlands) and Illumina (California).

What is covered in the report?

1. Overview of the cancer screening market.
2. Market drivers and challenges in the cancer screening market.
3. Market trends in the cancer screening market.
4. Historical, current and forecasted market size data for segments based on the type of end users (hospitals, laboratories ,independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (laboratory, genetic, imaging, biopsy and endoscopy).
6. Historical, current and forecasted market size data for segmentation based on application (lung, breast, melanoma, kidney, colorectal)
8. Historical, current and forecasted market size data for segments based on geography (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa)
9. Analysis of the competitive landscape and profiles of the major companies operating in the market

Why buy?

o Understand the demand for the cancer screening market to determine the viability of the market.
o Identify the developed and emerging markets where cancer screening market is operative.
o Identify the challenge areas and address them.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Recognize the key competitors of this market and respond accordingly.
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Global Cancer Screening Market (2018-2023) first appeared on CRI Report.

North America is leading the cancer screening market. The region is technologically equipped and being a developed economy it is efficiently catering to the rising incidence of cancer cases. The market is forecasted to grow at a compound annual growth rate (CAGR) f 11.14% resulting in an annual revenue of USD 16.36 Bn during the forecast period 2018-2023.
Companies are focusing on research & development (R&D) and entering into collaborations with the government to expand regional access.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic and biopsy will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into the United States Of America (U.S.A.) , Canada and others (the rest of North America).

Key growth factors

The rising incidence of cancer cases has led to a growing need among people to seek early cure and diagnosis. Technological advancements being adopted at a rapid pace to combat the rapid spread of cancer are the key growth factors for the market.

Threats and key players

The North America cancer screening market is a mature market for cancer screening and is forecasted to grow at a growth rate of 8.3%. But regulatory hindrances in the form of policies and norms which has the potential to impact the growth of the market.
Key players in the North America cancer screening market are GE Healthcare, Siemens Healthcare GmbH, Hologic Inc., Thermo Fisher Scientific, etc.

What is covered in the report?

1. Overview of the North America cancer screening market.
2. Market drivers and challenges in the North America cancer screening market.
3. Market trends in the North America cancer screening market.
4. Historical, current and forecasted market size data for the North America market segmentation based on type of end user (hospitals, laboratories , independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal)
5. Historical, current and forecasted market size data for the North America market segmentation based on type of end-user (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of cancer screening market by countries U.S.A., Canada and others (the rest of North America) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the North American market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.

The post North America Cancer Screening Market (2018-2023) first appeared on CRI Report.

The Middle East and Africa (MEA) cancer screening market is growing at a very slow rate. The MEA market is projected to reach USD 50.61 Bn by 2023, at a compound annual growth rate (CAGR) of 11.5% during the forecast period (2018-2023).The United Arab Emirates (UAE), Saudi Arabia and Kuwait are expected to drive the MEA cancer screening market while Africa will witness a moderate growth. Due to limited availability, the MEA occupies the least share in the market.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. Independent physicians and clinics along with hospitals will witness an optimistic growth during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Laboratory, biopsy and genetic tests will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Lung, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into UAE, Saudi Arabia and the rest of the MEA.

Key growth factors

The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.
Threats and key players
The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the MEA cancer screening market are Thermo Fisher Scientific, GE Healthcare, Siemens Healthcare, Roche Diagnostics and Illumina Inc.

What is covered in the report?

1. Overview of the MEA cancer screening market.
2. Market drivers and challenges in the MEA cancer screening market.
3. Market trends in the MEA cancer screening market.
4. Historical, current and forecasted market size data for MEA market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the MEA market segmentation based on type of end-user (hospitals, laboratory, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries and others (other parts of MEA) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the MEA market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.

The post MEA Cancer Screening Market (2018-2023) first appeared on CRI Report.

The Latin America cancer screening market is currently valued at USD 21.24 billion and is forecasted to achieve a growth rate of 7.19 % compound annual growth rate (CAGR) leading to a regional revenue of USD 30.06 Bn. Latin America’s growth is much slower compared to other regions. The region needs to work exclusively on its socio-economic and political framework to support the untapped growth of the cancer screening market.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The hospital and laboratory segment will witness a progressive growth during the forecast period 2018-2023. Independent physicians and clinics will witness a healthy growth rate of 6.28% during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and laboratory will be the leading segments during the forecast period 2018-2023 with biopsy witnessing a growth rate of 27.23% during the forecast period 2018-2023.

By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into Brazil, Colombia and the rest of Latin America.

Key growth factors

The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.

Threats and key players

The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the Latin America cancer screening market are Abbott diagnostics, Becton, Dickinson and Company, GE Healthcare, Roche Diagnostics and Hologic Inc.

What is covered in the report?

1. Overview of the Latin America cancer screening market.
2. Market drivers and challenges in the Latin America cancer screening market.
3. Market trends in the Latin America cancer screening market.
4. Historical, current and forecasted market size data for the Latin America market segmentation based on type of end users (Hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the Latin America market segmentation based on type of end users (Hospitals, laboratory, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of cancer screening market by countries and others (other parts of Europe) – by revenue
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the Latin American market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.

The post Latin America Cancer Screening Market (2018-2023) first appeared on CRI Report.

Europe after North America is the second largest market leading the cancer screening market. The market is forecasted to grow at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the forecast period (2018-2023). Increase in the aging population along with the rise in the number of cancer incidences is a key driving factor for the market. Western Europe is moving fast towards the adoption of performance-based remuneration systems.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and endoscopy will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into the United Kingdom (U.K.), France and Germany.

Key growth factors

Rise in the aging population, changing environmental conditions along with the adoption of a sedentary lifestyle is contributing to more cancer-related cases.

Threats and key players

Stringent regulations along with regulatory inter and intra state barriers pose many challenges for the region. Lack of associated funding and transparency in medical procedures turn out to be as threats to the market.
Key players in the European cancer screening market are F. Hoffman-La- Roche Ltd, Bayer AG, and Johnson & Johnson, Pfizer, Merck & co.

What is covered in the report?

1. Overview of the European cancer screening market.
2. Market drivers and challenges in the European cancer screening market.
3. Market trends in the European cancer screening market.
4. Historical, current and forecasted market size data for Europe market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) – by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for Europe market segmentation based on end-users (hospitals, laboratories, independent physicians and clinics) – by type of screening type(laboratory, genetic, imaging, biopsy and endoscopy) –by application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries UK, Germany and Others (Other parts of Europe) – by revenue .
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the European market.

Why buy?

o Understand the demand for the cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.

The post Europe Cancer Screening Market (2018-2023) first appeared on CRI Report.

The United States Of America (U.S.A.) is leading the cancer screening market. The rising incidence of cancer along with growing awareness regarding prevention of diseases and diagnosis is a key driver for the market. There is increased technological advancement along with fund based initiatives towards research and development (R&D) for awareness and prevention of diseases. The cancer screening market is expected to reach USD 13.12 Bn by 2023 growing at a CAGR of 10.95%.

Cancer screening market in the U.S.A. is classified by end users, screening type, and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type, it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal cancer.

Key growth factors

Increasing prevalence of cancer, funded initiatives from the government side and the growing trend to follow a sedentary lifestyle are the key growth factors for the region.

Threats and key players

Growing inter and intrastate barriers along with complicated frameworks has the potential to halt the growth of the market.
The key players operating in the U.S.A. cancer screening market are Roche Diagnostics, Abbott Laboratories, GE Healthcare Qiagen, Thermo Fisher Scientific and Siemens Healthineers

What is covered in the report?

1. Overview of the cancer screening market in the U.S.A.
2. Market drivers and challenges in the cancer screening market in the U.S.A.
3. Market trends in the cancer screening market in the U.S.A.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, laboratories and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application type (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand of cancer screening market in the U.S.A. to determine the viability of the market.
o Identify the developed and emerging markets where cancer screening market in the U.S.A. are sold.
o Identify the challenge areas and address them.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Cancer Screening Market in the U.S.A. (2018-2023) first appeared on CRI Report.

The United Kingdom (U.K.) stands next to the United States of America (U.S.A.) in coming up with latest technologies to combat the spread of cancer. The cancer screening market in the U.K. is expected to reach USD Bn by 2023 at a CAGR of 8.5%.
Cancer screening market in the U.K. is classified by end users, screening type, and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type, it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal type.

Key growth factors

Increasing prevalence of cancer, funded initiatives from the government side and the growing trend to follow a sedentary lifestyle are the key growth factors in this region.

Threats and key players

The complicated regulatory framework has the potential to halt the growth of the market. The exorbitant cost of the services and medicinal methodologies can cease he growth of the market.
The key players operating in the valve market are Abbott Healthcare, Agilent, Becton Dickinson, Biomedical Diagnostics, Qiagen, Thermo Fisher Scientific and Bio-Rad.

What is covered in the report?

1. Overview of the cancer screening market in the U.K.
2. Market drivers and challenges in the cancer screening market in the U.K.
3. Market trends in the cancer screening market in the U.K.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, laboratories and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application type (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in the U.K. to determine the viability of the market.
o Identify the developed and emerging markets where cancer screening market in the U.K. are sold.
o Identify the challenge areas and address them.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Cancer Screening Market in the U.K. (2018-2023) first appeared on CRI Report.

The Asia-Pacific is a growing region and holds lots of positive socio-economic factors suitable for the growth and progress of the market primarily because of its association with the global value chains (GVCs). India being a part of the Asia-Pacific region, holds key access to the region’s close association with trade agreements with global growth centers. The total market for diagnostic and medical equipment in India is worth USD 14.73 billion and is forecasted to expand at an annual rate of 13% CAGR during the forecast period 2018-2023.

Key growth factors

With the growing population, the cancer burden continues to grow in India. Hence, arises the need of more precision based medical technologies and methodologies to cater to the need of the region.

Threats and key players

Though the Indian market is burgeoning with opportunities .It needs to focus more on its tax regime and easier business conditions. More than 1 million cases of cancer are diagnosed in India every year and this number is bound to increase by 5 billion. Taking into considerations the risks, the region is bound to encounter human and economic costs from the increasing rate of cancer.
The key players operating in the cancer screening market are F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Siemens Healthineers, Philips and GE Healthcare.

What is covered in the report?

1. Overview of the cancer screening market in India.
2. Market drivers and challenges in the cancer screening market in India.
3. Market trends in the cancer screening market in India.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, laboratories, and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (Laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application type (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in India to determine the viability of the market.
o Identify the developed and emerging markets where cancer screening market in India is sold.
o Identify the challenge areas and address them.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Cancer Screening Market in India (2018-2023) first appeared on CRI Report.

China’s demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital investment. The cancer screening market in China is expected to reach USD 1.5 Bn by 2023 at 14 % CAGR.
The cancer screening market in China is classified by end users, screening type and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal cancer.

Key growth factors

Rise in the population along with an increase in the patient pool and favourable government policies is a key driver for the market. Also, there is an increase in the aging population, growing levels of pollution and a more sedentary lifestyle.

Threats and key players

Providing drugs at lower prices along with ensuring affordability as well as accessibility will be a major threat for the region. Transparency in medical treatment is being been demanded by people, hence, provision of accurate and proper treatment will be a disguised opportunity.
The key players operating in the valve market are Quest Diagnostics, Hologic Inc., Qiagen, F. Hoffmann-La Roche AG and Abbott Laboratories.

What is covered in the report?

1. Overview of the cancer screening market in China.
2. Market drivers and challenges in the cancer screening market in China.
3. Market trends in the cancer screening market in China.
4. Historical, current and forecasted market size data for segments based on end users (hospitals, Laboratories, and independent physicians and clinics).
5. Historical, current and forecasted market size data for segments based on screening type (Laboratory, genetic, biopsy, imaging and endoscopy testing).
6. Historical, current and forecasted market size data for segmentation based on application (lung, breast, melanoma, kidney and colorectal cancer).
7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in China to determine the viability of the market.
o Identify the developed and emerging markets where cancer screening market in China is sold.
o Identify the challenge areas and address them.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Cancer Screening Market in China (2018-2023) first appeared on CRI Report.

Asia-Pacific is a rapidly growing cancer market. The market is forecasted to grow at a compound annual growth rate (CAGR) of 17.3% resulting in annual revenue of USD 32.26 Bn during the forecast period (2018-2023). Asia Pacific is rapidly adopting the latest technological developments and is contributing towards exhaustive research initiatives to contribute to the growth of the cancer screening market.

By end users, the market is segmented into hospitals, laboratories, and independent physicians and clinics. Laboratories segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 Bn during the forecast period.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and endoscopy will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into India, China and the rest of Asia-Pacific.

Key growth factors

The growing patient pool in India, China nd Japan ue to the support in diagnostic process at comparatively lower prices, and a favourable regulatory framework are some of the factors boosting the market growth in this region.

Threats and key players

Regional trade barriers and stringent regulations will act as the obstacles. The need to adopt advanced technologies will aggravate the need for skilled professionals. Transparency in medicinal treatments will be a key challenge for the region.
Key players in the Asia-Pacific cancer screening market are Abbott diagnostics, GE healthcare, Hologic Inc., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.

What is covered in the report?

1. Overview of the Asia-Pacific cancer screening market.
2. Market drivers and challenges in Asia-Pacific cancer screening market.
3. Market trends in the Asia-Pacific cancer screening market.
4. Historical, current and forecasted market size data for the Asia-Pacific market segmentation based on type of end users (Hospitals, laboratories, independent physicians and clinics) – by screening type(Laboratory, genetic, imaging, biopsy and endoscopy) –by application (Lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the Asia-Pacific market segmentation based on end users (hospitals, laboratory, independent physicians and clinics) – by screening type(Laboratory, genetic, imaging, biopsy and endoscopy) –by application lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries and others (other parts of Europe) – by revenue.
7. Historical, current and forecasted market size data for country-wise segments – by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the European market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services with the key players in the market.

The post Asia Pacific Cancer Screening Market (2018-2023) first appeared on CRI Report.